PCSK9 inhibitors: from pre-clinical research to clinical practice.

1 September 2020 (15:00 - 15:08)

Organised by:

About the speaker

Doctor Christie Ballantyne

Baylor College of Medicine, Houston (United States of America)

4 More presentations in this session

Presentation thumbnail

PCSK9 inhibitors from bench to real world: a journey to improve CV outcomes in very high-risk patients. - Sponsored by Amgen (Europe) GmbH.

Presentation thumbnail

Managing patients with PCSK9 inhibitors: navigating the continuum of cardiovascular risk.

Professor G. De Ferrari (Turin, IT)

Presentation thumbnail

PCSK9 inhibitors: what can we learn from 5 years of real-world use? EU data.

Professor K. Ray (London, GB)

Presentation thumbnail

PCSK9 inhibitors: what can we learn from 5 years of real-world use? US/Canadian data.

Professor S. Goodman (Toronto, CA)

Access the full session

Session thumbnail

PCSK9 inhibitors from bench to real world: a journey to improve CV outcomes in very high-risk patients

The Event

ESC Congress 2020

1 September 2020 15:00 CET

You may be interested in

Congress Presentation

Novel insights into the management of German patients with very high cardiovascular risk eligible for PCSK9 inhibitor treatment: baseline characteristics from the PERI-DYS study

27 August 2021

Webinar

Injectable therapies for cardiovascular disease: optimising their use in practice - experiences from the UK and Italy

18 March 2022

Congress Presentation

Identification of potent small-molecule PCSK9 inhibitors based on quantitative structure-activity relationship, pharmacophore modeling, and molecular docking procedure.

28 August 2023

Webinar

LDL-C reduction postACS: strike early and strike strong

15 November 2021

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources